Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

ADVANCED ENZYME TECHNOLOGIES 2023-24 Annual Report Analysis
Wed, 3 Jul

ADVANCED ENZYME TECHNOLOGIES has announced its results for the year ended March 2024. Let us have a look at the detailed performance review of the company during FY23-24.

ADVANCED ENZYME TECHNOLOGIES Income Statement Analysis

  • Operating income during the year rose 15.4% on a year-on-year (YoY) basis.
  • The company's operating profit increased by 24.0% YoY during the fiscal. Operating profit margins witnessed a fall and down at 30.5% in FY24 as against 28.4% in FY23.
  • Depreciation charges increased by 0.6% and finance costs increased by 18.5% YoY, respectively.
  • Other income grew by 45.2% YoY.
  • Net profit for the year grew by 31.9% YoY.
  • Net profit margins during the year grew from 19.2% in FY23 to 22.0% in FY24.

ADVANCED ENZYME TECHNOLOGIES Income Statement 2023-24

No. of Mths Year Ending 12 Mar-23* 12 Mar-24* % Change
Net Sales Rs m 5,406 6,239 15.4%
Other income Rs m 255 370 45.2%
Total Revenues Rs m 5,661 6,608 16.7%
Gross profit Rs m 1,534 1,902 24.0%
Depreciation Rs m 350 352 0.6%
Interest Rs m 35 41 18.5%
Profit before tax Rs m 1,404 1,878 33.8%
Tax Rs m 365 509 39.3%
Profit after tax Rs m 1,039 1,370 31.9%
Gross profit margin % 28.4 30.5
Effective tax rate % 26.0 27.1
Net profit margin % 19.2 22.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Must See: These Segments are Witnessing Incredible Growth with Modi's Push

ADVANCED ENZYME TECHNOLOGIES Balance Sheet Analysis

  • The company's current liabilities during FY24 stood at Rs 1 billion as compared to Rs 776 million in FY23, thereby witnessing an increase of 37.1%.
  • Long-term debt down at Rs 70 million as compared to Rs 78 million during FY23, a fall of 10.8%.
  • Current assets rose 12% and stood at Rs 8 billion, while fixed assets rose 3% and stood at Rs 7 billion in FY24.
  • Overall, the total assets and liabilities for FY24 stood at Rs 15 billion as against Rs 14 billion during FY23, thereby witnessing a growth of 8%.

ADVANCED ENZYME TECHNOLOGIES Balance Sheet as on March 2024

No. of Mths Year Ending 12 Mar-23* 12 Mar-24* % Change
Networth Rs m 12,351 13,211 7.0
 
Current Liabilities Rs m 776 1,064 37.1
Long-term Debt Rs m 78 70 -10.8
Total Liabilities Rs m 14,105 15,212 7.8
 
Current assets Rs m 7,221 8,097 12.1
Fixed Assets Rs m 6,884 7,114 3.3
Total Assets Rs m 14,105 15,212 7.8
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



ADVANCED ENZYME TECHNOLOGIES Cash Flow Statement Analysis

  • ADVANCED ENZYME TECHNOLOGIES's cash flow from operating activities (CFO) during FY24 stood at Rs 1 billion, an improvement of 0.7% on a YoY basis.
  • Cash flow from investing activities (CFI) during FY24 stood at Rs -646 million on a YoY basis.
  • Cash flow from financial activities (CFF) during FY24 stood at Rs -592 million on a YoY basis.
  • Overall, net cash flows for the company during FY24 stood at Rs 173 million from the Rs -2 billion net cash flows seen during FY23.

ADVANCED ENZYME TECHNOLOGIES Cash Flow Statement 2023-24

Particulars No. of months 12 12 % Change
Year Ending Mar-23 Mar-24
Cash Flow from Operating Activities Rs m 1,404 1,414 0.7%
Cash Flow from Investing Activities Rs m -2,982 -646 -
Cash Flow from Financing Activities Rs m -258 -592 -
Net Cash Flow Rs m -1,709 173 -
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Current Valuations for ADVANCED ENZYME TECHNOLOGIES

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 12.2, an improvement from the EPS of Rs 9.3 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 368.5, stands at 30.1 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 3.1 times, while the price to sales ratio stands at 6.6 times.
  • The company's price to cash flow (P/CF) ratio stood at 21.4 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending 12 Mar-23* 12 Mar-24*
Sales per share (Unadj.) Rs 48.3 55.8
TTM Earnings per share Rs 9.3 12.2
Diluted earnings per share Rs 9.3 12.2
Price to Cash Flow x 18.7 21.4
TTM P/E ratio x 24.9 30.1
Price / Book Value ratio x 2.5 2.8
Market Cap Rs m 30,939 36,793
Dividends per share (Unadj.) Rs 1.0 5.1
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



Ratio Analysis for ADVANCED ENZYME TECHNOLOGIES

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 7.6x during FY24, from 9.3x during FY23. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 46.6x during FY24, from 41.4x during FY23. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company improved and stood at 10.4% during FY24, from 8.4% during FY24. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 14.5% during FY24, from 11.6% during FY23. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company improved and stood at 9.3% during FY24, from 7.6% during FY23. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending 12 Mar-23* 12 Mar-24*
Current ratio x 9.3 7.6
Debtors’ Days Days 68 58
Interest coverage x 41.4 46.6
Debt to equity ratio x 0.0 0.0
Return on assets % 7.6 9.3
Return on equity % 8.4 10.4
Return on capital employed % 11.6 14.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Accord Fintech, Equitymaster



To see how ADVANCED ENZYME TECHNOLOGIES has performed over the last 5 years, please visit here.

ADVANCED ENZYME TECHNOLOGIES Share Price Performance

Over the last one year, ADVANCED ENZYME TECHNOLOGIES share price has moved up from Rs 282.6 to Rs 368.5, registering a gain of Rs 85.9 or around 30.4%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 37,159.3 (down 0.3%). Over the last one year it has moved up from 25,627.6 to 37,159.3, a gain of 11,532 points (up 45.0%).

Overall, the S&P BSE SENSEX is up 21.8% over the year.

(To know more, check out historical annual results for ADVANCED ENZYME TECHNOLOGIES and quarterly results for ADVANCED ENZYME TECHNOLOGIES)

Annual Report FAQs

What is the current share price of ADVANCED ENZYME TECHNOLOGIES?

ADVANCED ENZYME TECHNOLOGIES currently trades at Rs 366.7 per share. You can check out the latest share price performance of ADVANCED ENZYME TECHNOLOGIES here...

What was the revenue of ADVANCED ENZYME TECHNOLOGIES in FY24? How does it compare to earlier years?

The revenues of ADVANCED ENZYME TECHNOLOGIES stood at Rs 6,608 m in FY24, which was up 16.7% compared to Rs 5,661 m reported in FY23.

ADVANCED ENZYME TECHNOLOGIES' revenue has grown from Rs 4,499 m in FY20 to Rs 6,608 m in FY24.

Over the past 5 years, the revenue of ADVANCED ENZYME TECHNOLOGIES has grown at a CAGR of 10.1%.

What was the net profit of ADVANCED ENZYME TECHNOLOGIES in FY24? How does it compare to earlier years?

The net profit of ADVANCED ENZYME TECHNOLOGIES stood at Rs 1,370 m in FY24, which was up 31.9% compared to Rs 1,039 m reported in FY23.

This compares to a net profit of Rs 1,238 m in FY22 and a net profit of Rs 1,513 m in FY21.

Over the past 5 years, ADVANCED ENZYME TECHNOLOGIES net profit has grown at a CAGR of 0.7%.

What does the cash flow statement of ADVANCED ENZYME TECHNOLOGIES reveal?

The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.

This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.

The cash flow statement of ADVANCED ENZYME TECHNOLOGIES reveals:

  • Cash flow from operations increased in FY24 and stood at Rs 1,414 m as compared to Rs 1,404 m in FY23.
  • Cash flow from investments increased in FY24 and stood at Rs -646 m as compared to Rs -2,982 m in FY23.
  • Cash flow from financial activity decreased in FY24 and stood at Rs -592 m as compared to Rs -258 m in FY23.

Here's the cash flow statement of ADVANCED ENZYME TECHNOLOGIES for the past 5 years.

(Rs m)FY20FY21FY22FY23FY24
From Operations1,4091,6301,2231,4041,414
From Investments-445-260-38-2,982-646
From Financial Activity-386-264-485-258-592
Net Cashflow5961,093754-1,709173

What does the Key Ratio analysis of ADVANCED ENZYME TECHNOLOGIES reveal?

Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.

The ratio/financial analysis of ADVANCED ENZYME TECHNOLOGIES reveals:

  • Operating profit margins witnessed a fall and down at 30.5% in FY24 as against 28.4% in FY23.
  • Net profit margins grew from 19.2% in FY23 to 22.0% in FY24.
  • Debt to Equity ratio for FY24 stood at 0.0 as compared to 0.0 in FY23.

Here's the ratio/financial analysis of ADVANCED ENZYME TECHNOLOGIES for the past 5 years.

 FY20FY21FY22FY23FY24
Operating Profit Margin (%)45.846.338.328.430.5
Net Profit Margin (%)30.030.123.419.222.0
Debt to Equity Ratio (x)0.00.00.00.00.0

 

Equitymaster requests your view! Post a comment on "ADVANCED ENZYME TECHNOLOGIES 2023-24 Annual Report Analysis". Click here!